Identification of Small-Molecule Antagonists Targeting the Growth Hormone Releasing Hormone Receptor (GHRHR).


Journal

Journal of chemical information and modeling
ISSN: 1549-960X
Titre abrégé: J Chem Inf Model
Pays: United States
ID NLM: 101230060

Informations de publication

Date de publication:
29 Aug 2024
Historique:
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: aheadofprint

Résumé

The growth hormone-releasing hormone receptor (GHRHR) belongs to Class B1 of G protein-coupled receptors (GPCRs). Class B1 GPCR peptides such, as growth hormone-releasing hormone (GHRH), have been proposed to bind in a two-step model, where first the C-terminal region of the peptide interacts with the extracellular domain of the receptor and, subsequently, the N-terminus interacts with the seven transmembrane domain of the receptor, resulting in activation. The GHRHR has recently been highlighted as a promising drug target toward several types of cancer and has been shown to be overexpressed in prostate, breast, pancreatic, and ovarian cancer. Indeed, peptide GHRHR antagonists have displayed promising results in many cancer models. However, no nonpeptide GHRHR-targeting compounds have yet been identified. We have utilized several computational tools to target GHRHR and identify potential small-molecule compounds directed at this receptor. These compounds were validated

Identifiants

pubmed: 39207455
doi: 10.1021/acs.jcim.4c00577
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Minos-Timotheos Matsoukas (MT)

University of West Attica, Department of Biomedical Engineering, Athens 12243, Greece.

Tarryn Radomsky (T)

Centre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.
Department of Physiology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.

Vasilis Panagiotopoulos (V)

University of West Attica, Department of Biomedical Engineering, Athens 12243, Greece.

Robin du Preez (RD)

Centre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.
Department of Physiology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.

Michail Papadourakis (M)

Cloudpharm PC, Athens 15125, Greece.

Konstantinos Tsianakas (K)

University of West Attica, Department of Biomedical Engineering, Athens 12243, Greece.

Robert P Millar (RP)

Centre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.
Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9JZ, U.K.
Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
School of Medicine, University of St Andrews, St Andrews KY16 9TF, U.K.

Ross C Anderson (RC)

Centre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.
Department of Physiology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.

Georgios A Spyroulias (GA)

University of Patras, School of Health Sciences, Department of Pharmacy, University Campus, Rion, Patras 26500, Greece.

Claire L Newton (CL)

Centre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.
Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9JZ, U.K.

Classifications MeSH